ArticleHaematologica2018
Meaningful changes in end-of-life care among patients with myeloma.
Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Disparities in Multiple Myeloma Treatment Patterns in the United States: A Systematic Review.Clinical lymphoma, myeloma & leukemia · 2023Pooled it
- Recent Updates and Advancements in the Diagnosis and Management of Plasma Cell Dyscrasias.Cureus · 2026Review
- Perceived Value of Transfusion Access and Hospice Services Among Patients With Blood Cancers.JAMA network open · 2025Article
- Challenges in hospice and end-of-life care in the transfusion-dependent patient.Hematology. American Society of Hematology. Education Program · 2024Review
- Utilization and quality of palliative care in patients with hematological and solid cancers: a population-based study.Journal of cancer research and clinical oncology · 2024Article
- Perspectives on Transfusions for Hospice Patients With Blood Cancers: A Survey of Hospice Providers.Journal of pain and symptom management · 2024Article
- End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy.Frontiers in oncology · 2024Article
- Place of Death for Israeli Cancer Patients Over a 20-Year Period: Reducing Hospital Deaths, but Barriers Remain.The oncologist · 2023Article
- High Hospital-related Costs at the End-of-life in Patients With Multiple Myeloma: A Single-center Study.HemaSphere · 2023Article
- Advancing Palliative Care Integration in Hematology: Building Upon Existing Evidence.Current treatment options in oncology · 2023Review
- Goal of a "Good Death" in End-of-Life Care for Patients with Hematologic Malignancies-Are We Close?Current hematologic malignancy reports · 2021Review
- Article
- Preference for Aggressive End-of-Life Care among Advanced Cancer Patients in Wuhan, China: A Cross-Sectional Study.International journal of environmental research and public health · 2020Article
- Palliative and End-of-Life Care for Patients With Hematologic Malignancies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Review
- Cost differential associated with hospice use among older patients with multiple myeloma.Journal of geriatric oncology · 2020Article
- Disparities in place of death for patients with hematological malignancies, 1999 to 2015.Blood advances · 2019Article
- Supporting self-management in palliative care throughout the cancer care trajectory.Current opinion in supportive and palliative care · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Patients with advanced myeloma experience a high symptom burden particularly near the end of life, making timely hospice use crucial. Little is known about the quality and determinants of end-of-life care for this population, including whether potential increases in hospice use are also accompanied by "late" enrollment (≤ 3 days before death). Using the Surveillance, Epidemiology, and End-Results-Medicare database, we identified patients ≥ 65 years diagnosed with myeloma between 2000 and 2013 who died by December 31, 2013. We assessed prevalence and trends in hospice use, including late enrollment. We also examined six established measures of potentially aggressive medical care at the end of life. Independent predictors of late hospice enrollment and aggressive end-of-life care were assessed using multivariable logistic regression analyses. Of 12,686 myeloma decedents, 48.2% enrolled in hospice. Among the 6111 who enrolled, 17.2% spent ≤ 3 days there. There was a significant trend in increasing hospice use, from 28.5% in 2000 to 56.5% by 2013 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.